Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSEMBLE-1 short-course radiotherapy followed by CAPOX for locally advanced rectal cancer
jRCTs051200113Phase 2Active, not recruiting
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer. Primary endpoint: Pathological complete response. Started Jan 2021; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs051200113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200113.